Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the activity of SU011248 in subjects with
cisplatin-refractory or multiply relapsed germ cell cancer. It is believed that SU011248
treatment may prove to increase disease response.
Phase:
Phase 2
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborators:
Canadian Urologic Oncology Group German Testicular Cancer Study Group NCIC Testis Group